Imvotamab, a CD20 x CD3 bispecific monoclonal antibody, offers potential for deeper B cell depletion than currently approved therapiesMOUNTAIN VIEW, Calif., May 31, 2023 IGM Biosciences, Inc. ,. | May 31, 2023
Operator: Good day, everyone, and welcome to the IGM Biosciences Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Today s call is being recorded.